Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D, Wang L, Bidshahri R, Kraft L, Hwang Y, Žentelis S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic M, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falconer E. Jones BE, et al. Among authors: dittmann m. bioRxiv [Preprint]. 2020 Oct 9:2020.09.30.318972. doi: 10.1101/2020.09.30.318972. bioRxiv. 2020. PMID: 33024963 Free PMC article. Updated. Preprint.
Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia.
Bernard-Raichon L, Venzon M, Klein J, Axelrad JE, Zhang C, Sullivan AP, Hussey GA, Casanovas-Massana A, Noval MG, Valero-Jimenez AM, Gago J, Putzel G, Pironti A, Wilder E; Yale IMPACT Research Team; Thorpe LE, Littman DR, Dittmann M, Stapleford KA, Shopsin B, Torres VJ, Ko AI, Iwasaki A, Cadwell K, Schluter J. Bernard-Raichon L, et al. Among authors: dittmann m. Nat Commun. 2022 Nov 1;13(1):5926. doi: 10.1038/s41467-022-33395-6. Nat Commun. 2022. PMID: 36319618 Free PMC article.
Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.
Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, Rajsbaum R, Menachery VD. Lokugamage KG, et al. Among authors: dittmann m. bioRxiv [Preprint]. 2020 Jul 13:2020.03.07.982264. doi: 10.1101/2020.03.07.982264. bioRxiv. 2020. PMID: 32511335 Free PMC article. Updated. Preprint.
A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. de Vries M, et al. Among authors: dittmann m. bioRxiv [Preprint]. 2021 Feb 19:2020.08.28.272880. doi: 10.1101/2020.08.28.272880. bioRxiv. 2021. PMID: 32869028 Free PMC article. Updated. Preprint.
Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.
Noval MG, Kaczmarek ME, Koide A, Rodriguez-Rodriguez BA, Louie P, Tada T, Hattori T, Panchenko T, Romero LA, Teng KW, Bazley A, de Vries M, Samanovic MI, Weiser JN, Aifantis I, Cangiarella J, Mulligan MJ, Desvignes L, Dittmann M, Landau NR, Aguero-Rosenfeld M, Koide S, Stapleford KA. Noval MG, et al. Among authors: dittmann m. Sci Rep. 2021 Mar 10;11(1):5538. doi: 10.1038/s41598-021-84913-3. Sci Rep. 2021. PMID: 33692390 Free PMC article.
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.
Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D, Wang L, Zhang Y, Yang ES, Bidshahri R, Kraft L, Hwang Y, Žentelis S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic MI, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falconer E. Jones BE, et al. Among authors: dittmann m. Sci Transl Med. 2021 May 12;13(593):eabf1906. doi: 10.1126/scitranslmed.abf1906. Epub 2021 Apr 5. Sci Transl Med. 2021. PMID: 33820835 Free PMC article.
Generation of quality-controlled SARS-CoV-2 variant stocks.
de Vries M, Ciabattoni GO, Rodriguez-Rodriguez BA, Crosse KM, Papandrea D, Samanovic MI, Dimartino D, Marier C, Mulligan MJ, Heguy A, Desvignes L, Duerr R, Dittmann M. de Vries M, et al. Among authors: dittmann m. Nat Protoc. 2023 Dec;18(12):3821-3855. doi: 10.1038/s41596-023-00897-6. Epub 2023 Oct 13. Nat Protoc. 2023. PMID: 37833423 Review.
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, Rajsbaum R, Menachery VD. Lokugamage KG, et al. Among authors: dittmann m. J Virol. 2020 Nov 9;94(23):e01410-20. doi: 10.1128/JVI.01410-20. Print 2020 Nov 9. J Virol. 2020. PMID: 32938761 Free PMC article.
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. de Vries M, et al. Among authors: dittmann m. J Virol. 2021 Mar 10;95(7):e01819-20. doi: 10.1128/JVI.01819-20. Epub 2021 Feb 23. J Virol. 2021. PMID: 33622961 Free PMC article.
The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response.
Seifert LL, Si C, Saha D, Sadic M, de Vries M, Ballentine S, Briley A, Wang G, Valero-Jimenez AM, Mohamed A, Schaefer U, Moulton HM, García-Sastre A, Tripathi S, Rosenberg BR, Dittmann M. Seifert LL, et al. Among authors: dittmann m. PLoS Pathog. 2019 Nov 4;15(11):e1007634. doi: 10.1371/journal.ppat.1007634. eCollection 2019 Nov. PLoS Pathog. 2019. PMID: 31682641 Free PMC article.
129 results